Elaina Haeuber

Clinical Development

Bringing an Oncology Asset to Market: In-House vs Outsource?

During the multifaceted journey of bringing a promising therapeutic to market, sponsors are faced with a critical choice—whether to manage asset development in-house or to outsource to a clinical research organization (CRO) partner. This decision can influence timelines, costs, control...